Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia, drawn from the whole corpus: 8 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Whether a menin inhibitor added to first-line therapy raises cure rates in NPM1-mutated AML.
MEN1 resistance mutations and how to sequence or combine inhibitors around them.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Dosing menin inhibitors safely with azoles and other QT-prolonging drugs.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 10 changes by month →When this page itself was last checked or edited.
Relapsed/refractory NPM1-mutated AML with no satisfactory alternative
CR 23%, ORR 33%, median OS 6.
A milestone in how this cancer is treated.
CR+CRh 22.
A milestone in how this cancer is treated.